Minireviews
Copyright ©The Author(s) 2021.
World J Clin Oncol. May 24, 2021; 12(5): 323-334
Published online May 24, 2021. doi: 10.5306/wjco.v12.i5.323
Figure 1
Figure 1 Graphical summary of different responses to immunotherapy. Pseudoprogression: increase of longest diameter > 20% at first follow-up, followed by a decrease of > 30% at subsequent follow-up. Dissociated response: increase of some target lesions of > 20% and reduction of at least another target lesion > 30% at follow-up. Hyperprogression: significant increase of target lesion at first follow-up; a baseline study is needed to correctly assess the hyperprogression. T: Time; TV: Tumor volume.